Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CAMP
Strong SellSinkerCAMP4 THERAPEUTICS CORPORATION · Healthcare · United States · $260M · Avg Vol: $1M/d
COMPANY DESCRIPTION
CAMP4 THERAPEUTICS CORPORATION is a biotechnology company developing a new class of RNA-targeting therapeutics designed to upregulate gene expression. Operating in the nascent and high-potential field of RNA modulation, CAMP4 aims to address diseases by precisely controlling gene expression with novel small molecule approaches. This clinical-stage biotech company leverages its proprietary RNA-targeting platform to develop first-in-class treatments for severe diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0.3M | 0.7M | 3.5M | 216.1% | 4.2M | 7.3M | 6.1M | 31.7% |
| EPS | -1.37 | -1.53 | -4.29 | -2.65 | — | -2.31 | — | — | — |
| Shares | 51.9M | 51.9M | 51.9M | 51.9M | -0.0% | 62.8M | — | — | — |
| Debt | 12.4M | 11.7M | 8.5M | 2.0M | -45.8% | 2.4M | — | — | — |
| Equity | -77.5M | -123.7M | 63.1M | 47.7M | -24.5% | — | — | — | — |
| Op CF | -38.5M | -44.2M | -45.6M | -29.6M | — | -28.6M | — | — | — |
| Inv CF | -4.0M | -0.7M | -0.4M | -0.2M | — | — | — | — | — |
| Fin CF | 100.2M | 0.3M | 71.7M | 75.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CAMP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CAMP | CAMP4 THERAPEUTICS CORPORATION(you) | $260M | 10 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
| AVXL | Anavex Life Sciences Corp. | $277M | 9 | Strong Sell |
| RNA | Atrium Therapeutics, Inc. | $233M | 11 | Strong Sell |
| TARA | Protara Therapeutics, Inc. | $226M | 9 | Strong Sell |
| NBP | NovaBridge Biosciences | $213M | 10 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $290M | 12 | Strong Sell |
| NERV | Minerva Neurosciences, Inc. | $231M | 12 | Strong Sell |
| IVVD | Invivyd, Inc. | $284M | 12 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%